CXCR4 and Miyoshi myopathy: Additionally, preclinical studies showed that concurrent CXCR4 and anti-BCMA CAR expression on NK cells effectively inhibited MM progression in mouse models [140].Ulocuplumab, the first mAb targeting CXCR4, has shown promise in a phase Ib/II study focused on R/RMM [141].